Drug Profile
Research programme: small-molecule skin cancer therapeutics - Pierre Fabre/Redx Pharma
Latest Information Update: 28 Apr 2018
Price :
$50
*
At a glance
- Originator Pierre Fabre; Redx Pharma
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Skin cancer
Most Recent Events
- 28 Apr 2018 No recent reports of development identified for research development in Skin-cancer in France
- 28 Apr 2018 No recent reports of development identified for research development in Skin-cancer in United Kingdom
- 06 Mar 2014 Redx Pharma and Pierre Fabre enter into a collaboration and option agreement